ATCC (American Type Culture Collection)
ATCC is a nonprofit biological resource center, with a nearly century-long legacy supporting public health, biodefense, and global health security. ATCC provides critical infrastructure for infectious disease research and CBR threat response. Our biorepository operations support federal agencies, academia, and industry through secure specimen handling, reagent authentication, and global distribution. ATCC manages over 22 million vials under federal contracts, including repositories for NIAID, CDC, BARDA, NCI, FDA, and USDA. These programs enable rapid deployment of validated biological materials for vaccine development, diagnostic assay verification, and therapeutic screening against high-consequence pathogens such as SARS-CoV-2. Certified under ISO 9001, 13485, 17025, and 17034, ATCC ensures quality, traceability, and regulatory compliance across its operations. Our high-containment laboratories (BSL-2 and BSL-3, with access to BSL-4 through partners) and Select Agent license position us to support MTEC-aligned efforts in emerging infectious diseases and medical countermeasure development for CBRN threats.
Industries
Nr. of Employees
large (251-1000)
ATCC (American Type Culture Collection)
10801 University Blvd, Manassas, VA 20110, USA
Patents
Products
Authenticated cell line collections
Curated collections of continuous cell lines, primary cells, engineered lines, and 3‑D tumor organoids provided as authenticated biological materials with provenance and annotation for research and assay use.
Microbial and viral strain libraries and panels
Extensive collections of bacterial, viral, fungal, and protist strains and curated panels for infectious disease research, QC, environmental testing, and assay development, including outbreak-relevant isolates.
Genomic and synthetic nucleic acid reference materials
Authenticated genomic DNA, synthetic nucleic acids, and associated sequence data provided as reference controls for molecular diagnostics, assay validation, and regulatory submissions.
Patient-derived tumor model sets with linked metadata
Next-generation cancer models derived from patient tumor tissue with accompanying anonymized clinical information and complete genetic analysis, produced and distributed to support translational and drug-resistance research.
Zika virus strains and nucleic acid controls
Tissue culture-adapted Zika virus strains, inactivated preparations, and synthetic nucleic acid materials released to support diagnostic and vaccine R&D during the Zika outbreak.
Authenticated cell line collections
Curated collections of continuous cell lines, primary cells, engineered lines, and 3‑D tumor organoids provided as authenticated biological materials with provenance and annotation for research and assay use.
Microbial and viral strain libraries and panels
Extensive collections of bacterial, viral, fungal, and protist strains and curated panels for infectious disease research, QC, environmental testing, and assay development, including outbreak-relevant isolates.
Genomic and synthetic nucleic acid reference materials
Authenticated genomic DNA, synthetic nucleic acids, and associated sequence data provided as reference controls for molecular diagnostics, assay validation, and regulatory submissions.
Patient-derived tumor model sets with linked metadata
Next-generation cancer models derived from patient tumor tissue with accompanying anonymized clinical information and complete genetic analysis, produced and distributed to support translational and drug-resistance research.
Zika virus strains and nucleic acid controls
Tissue culture-adapted Zika virus strains, inactivated preparations, and synthetic nucleic acid materials released to support diagnostic and vaccine R&D during the Zika outbreak.
Expertise Areas
- Cell line engineering and isogenic model development
- GMP cell banking and cryopreservation
- Large-scale biorepository operations and specimen logistics
- Cell authentication and STR-based identity testing (including nonhuman markers)
Key Technologies
- Genome editing (CRISPR-based workflows)
- Multiplex STR profiling and authentication assays
- Next-generation sequencing and transcriptomics
- Droplet digital PCR and quantitative nucleic acid assays
Key People
Senior Vice President, ATCC Federal Solutions
Director, Government Programs, ATCC Federal Solutions (AFS)
Director, Contracts, ATCC Federal Solutions (AFS)
Senior Vice President, ATCC Federal Solutions
Director, Government Programs, ATCC Federal Solutions (AFS)
Director, Contracts, ATCC Federal Solutions (AFS)
News & Updates
Ruth Cheng, appointed new president and CEO of ATCC, succeeds Raymond Cypess, who will remain on the Board of Directors as chairman.
NCI awarded ATCC a 5-year contract with a ceiling value of $4.06 million to provide lab services that support HIV and HTLV-1 research and vaccine development.
ATCC awarded a one-year, subaward in the amount of $165,962 from NIAID to collaborate on babesiosis and tickborne disease research.
ATCC received a C06 Research Facilities Construction Grant from ORIP, part of the NIH, to support the building of ATCC’s new biomanufacturing suite at its headquarters in Manassas, VA.
ATCC was awarded a contract to develop well-characterized challenge materials, enhancing their capabilities in infectious disease research.
A discussion on the importance of a unified approach to infectious disease management.
Ruth Cheng, appointed new president and CEO of ATCC, succeeds Raymond Cypess, who will remain on the Board of Directors as chairman.
NCI awarded ATCC a 5-year contract with a ceiling value of $4.06 million to provide lab services that support HIV and HTLV-1 research and vaccine development.
ATCC awarded a one-year, subaward in the amount of $165,962 from NIAID to collaborate on babesiosis and tickborne disease research.
ATCC received a C06 Research Facilities Construction Grant from ORIP, part of the NIH, to support the building of ATCC’s new biomanufacturing suite at its headquarters in Manassas, VA.
ATCC was awarded a contract to develop well-characterized challenge materials, enhancing their capabilities in infectious disease research.
A discussion on the importance of a unified approach to infectious disease management.